Large Cell Neuroendocrine Carcinoma — Trials

Large Cell Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

24 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 9
Ph III recruiting: 0
Growth YoY: —
Industry share: 40%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04079712	Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors	active not recruiting	Phase 2	17	National Cancer Institute (NCI)NIH	2	Sep 22, 2026	clinicaltrials
NCT06736418	Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy	active not recruiting	Phase 1	17	Abdera Therapeutics Inc.INDUSTRY	1	Apr 24, 2026